IDH2 and acute myeloid leukemia: Enasidenib is currently being evaluated as combination therapy for R/R IDH2-mutated AML in phase 1b/2 studies with venetoclax (NCT04092179) and decitabine/cedazuridine with venetoclax (NCT04774393), with preliminary data presented at ASH 2023 showing feasibility and favorable outcomes with both combinations [72, 83].